Sam Altman, Valley VCs Bet $48 Million on Blood-Testing Startup
Years after Theranos, Vital Biosciences wants to prove Silicon Valley really can disrupt blood testing.
This article is for subscribers only.
Vital Biosciences Inc. plans to unveil new technology on Monday that it says can use a few drops of blood for 50 lab-grade tests in 20 minutes.
The idea will give cold sweats to any investor familiar with Theranos Inc. That company, too, aimed to run large numbers of tests on small amounts of blood. It didn’t work, and its founder, Elizabeth Holmes, is currently serving 11 years in prison for fraud after the company rode a $9 billion valuation down to zero.